Zymeworks Inc. $ZYME Shares Sold by Citigroup Inc.

Citigroup Inc. trimmed its position in shares of Zymeworks Inc. (NASDAQ:ZYME) by 24.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 117,804 shares of the company’s stock after selling 38,194 shares during the period. Citigroup Inc. owned approximately 0.16% of Zymeworks worth $2,012,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. EcoR1 Capital LLC increased its stake in Zymeworks by 33.1% during the second quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company’s stock worth $288,278,000 after acquiring an additional 5,710,840 shares during the last quarter. Rubric Capital Management LP increased its position in Zymeworks by 8.6% during the 2nd quarter. Rubric Capital Management LP now owns 4,710,551 shares of the company’s stock worth $59,117,000 after purchasing an additional 372,107 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Zymeworks by 169.2% in the third quarter. Assenagon Asset Management S.A. now owns 1,326,774 shares of the company’s stock valued at $22,661,000 after buying an additional 833,994 shares during the period. Vestal Point Capital LP grew its stake in Zymeworks by 130.0% during the second quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $14,432,000 after buying an additional 650,000 shares during the period. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Zymeworks in the second quarter worth $5,974,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ZYME. Wells Fargo & Company raised shares of Zymeworks from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $25.00 to $33.00 in a research report on Friday, December 12th. Leerink Partners raised their target price on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Truist Financial started coverage on shares of Zymeworks in a research report on Wednesday, December 17th. They issued a “buy” rating and a $40.00 price objective for the company. Stifel Nicolaus boosted their target price on shares of Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, HC Wainwright raised their price target on shares of Zymeworks from $32.00 to $46.00 and gave the company a “buy” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.10.

Zymeworks News Summary

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: HC Wainwright raised its price target to $46 and reiterated a Buy rating — the new target implies substantial upside from current levels. Benzinga
• Positive Sentiment: Stifel Nicolaus boosted its price target to $47, another significant upward revision that supports a bullish view on ZYME’s longer‑term recovery. Stifel Target
• Positive Sentiment: Leerink Partners published a bullish forecast for Zymeworks, contributing to the cluster of upgrades and positive analyst sentiment this week. Leerink Report
• Neutral Sentiment: Lifesci Capital updated its FY-2026 and quarterly EPS forecasts with mixed changes: it materially improved the FY-2026 loss estimate (from -$1.40 to -$0.68) and sharply raised Q2/Q3 outlooks, but it lowered the Q1 estimate — a mixed signal that improves multi‑quarter visibility while acknowledging near‑term pressure. Lifesci Estimates
• Negative Sentiment: Recent quarterly results (reported March 2) showed a meaningful EPS miss and a ~92% YoY revenue decline, leaving Zymeworks unprofitable with negative margins — fundamentals that likely temper enthusiasm and explain part of the intraday weakness despite upgrades. Earnings Detail

Insider Transactions at Zymeworks

In other news, COO Mark Hollywood sold 6,120 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $138,740.40. Following the completion of the sale, the chief operating officer directly owned 132,913 shares in the company, valued at approximately $3,013,137.71. The trade was a 4.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey T. L. Smith sold 10,538 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25.10, for a total value of $264,503.80. Following the transaction, the executive vice president owned 18,352 shares in the company, valued at $460,635.20. This trade represents a 36.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 187,933 shares of company stock worth $4,673,716 in the last quarter. Insiders own 33.51% of the company’s stock.

Zymeworks Price Performance

ZYME opened at $24.08 on Monday. Zymeworks Inc. has a 12-month low of $9.03 and a 12-month high of $28.49. The stock has a market capitalization of $1.78 billion, a PE ratio of -22.30 and a beta of 1.23. The firm’s fifty day moving average price is $23.72 and its 200 day moving average price is $21.17.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Monday, March 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The company had revenue of $2.52 million during the quarter, compared to the consensus estimate of $21.78 million. Zymeworks had a negative return on equity of 26.00% and a negative net margin of 76.56%.Zymeworks’s revenue for the quarter was down 91.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.31) EPS.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.